Maurice Slevin

Maurice Slevin
CitizenshipUnited Kingdom
EducationUniversity of Cape Town
OccupationOncologist
Known forCancerbackup
Medical career
ResearchOncology

Maurice Slevin is a British medical oncologist specialising in the treatment of breast, ovarian and gastrointestinal cancers.[1] He has made contributions to the field through both his clinical practise and research.[2] He practised at St Bartholomew's Hospital and was a founding partner of Leaders in Oncology Care (LOC) on Harley Street.[3][4]

Education

Slevin graduated from the University of Cape Town and completed his postgraduate training at Groote Schuur Hospital in Cape Town and St Bartholomew's Hospital in London, where he worked as head of chemotherapy for solid cancers.[5][6][7] He is a Fellow of the Royal College of Physicians.

Career

His research primarily focused on clinical pharmacology, with particular emphasis on etoposide and cytosine arabinoside, as well as psychosocial oncology.[3][8][9][10] He has published over 150 peer-reviewed papers in academic journals and has an h-index of 58.[11][12]

He helped establish the cancer support charity Cancerbackup, which he chaired from 1985 to 2008, when it merged with Macmillan.[13][14][15][16]

Slevin and his colleagues carried out a study, funded by the Imperial Cancer Research Fund, which showed that cancer patients were more likely to opt for radical and intensive treatment with minimal chance of benefit than were their doctors.[17]

Slevin gained attention for his controversial papers on the National Health Service (NHS), where he argued that reform was more crucial than increased funding.[2][18][19] He suggested that the NHS had almost as many managers as nurses, a claim that was slammed by the NHS federation.[20] He led a movement in 2000 demanding a wholesale overhaul of NHS treatment of the disease, along with Karol Sikora, in which they argued for faster cancer treatment timelines.[21]

Slevin was a founder member of Doctors for Reform, a group of 1000 consultants who advocated a social insurance model of funding the NHS.[22]

Publications

Slevin has over 150 published peer-reviewed papers in academic journals, including:[23][11]

  • Slevin, M L; Clark, P I; Joel, S P; Malik, S; Osborne, R J; Gregory, W M; Lowe, D G; Reznek, R H; Wrigley, P F (1989). "A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer". Journal of Clinical Oncology. 7 (9): 1333–1340. doi:10.1200/JCO.1989.7.9.1333. ISSN 0732-183X. PMID 2549204.
  • Clark, P I; Slevin, M L; Joel, S P; Osborne, R J; Talbot, D I; Johnson, P W; Reznek, R; Masud, T; Gregory, W; Wrigley, P F (1994). "A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity". Journal of Clinical Oncology. 12 (7): 1427–1435. doi:10.1200/JCO.1994.12.7.1427. ISSN 0732-183X. PMID 8021734.
  • Slevin, M L (1990). "Low-dose oral etoposide: a new role for an old drug?". Journal of Clinical Oncology. 8 (10): 1607–1609. doi:10.1200/JCO.1990.8.10.1607. ISSN 0732-183X. PMID 2170588.
  • Slevin, M L; Piall, E M; Aherne, G W; Harvey, V J; Johnston, A; Lister, T A (1983). "Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid". Journal of Clinical Oncology. 1 (9): 546–551. doi:10.1200/JCO.1983.1.9.546. ISSN 0732-183X. PMID 6583325.
  • Slevin ML, Piall EM, Aherne GW, Johnston A, Sweatman MC, Lister TA (October 1981). "The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia". British Journal of Clinical Pharmacology. 12 (4): 507–10. doi:10.1111/j.1365-2125.1981.tb01258.x. PMC 1401912. PMID 6945865.
  • Slevin ML, Stubbs L, Plant HJ, Wilson P, Gregory WM, Armes PJ, Downer SM (June 1990). "Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public". BMJ (Clinical Research Ed.). 300 (6737): 1458–60. doi:10.1136/bmj.300.6737.1458. PMC 1663147. PMID 2379006.
  • Slevin M, Mossman J, Bowling A, Leonard R, Steward W, Harper P, McIllmurray M, Thatcher N (June 1995). "Volunteers or victims: patients' views of randomised cancer clinical trials". British Journal of Cancer. 71 (6): 1270–4. doi:10.1038/bjc.1995.245. PMC 2033847. PMID 7779722.
  • Slevin ML, Terry Y, Hallett N, Jefferies S, Launder S, Plant R, Wax H, McElwain T (September 1988). "BACUP--the first two years: evaluation of a national cancer information service". BMJ (Clinical Research Ed.). 297 (6649): 669–72. doi:10.1136/bmj.297.6649.669. PMC 1834344. PMID 3140928.

References

  1. ^ Slevin, Maurice L. (2003). Resuscitating the NHS (PDF). Centre for Policy Studies. ISBN 1-903219-50-7.
  2. ^ a b "NHS could implode say doctors". BBC NEWS. 2003-02-03. Retrieved 2024-09-09.
  3. ^ a b "How doctors care for their own families' futures". The Telegraph. 2016-02-23. Retrieved 2024-09-09.
  4. ^ Slevin, Maurice L. (2015). Every Rational Attempt: The Stories Behind The Contribution of Barts In The Fight Against Cancer (PDF). London: Barts Cancer Institute, Queen Mary University of London. ISBN 978-1-326-33764-3.
  5. ^ "Reunions held in 2013: Class of 1973 reunion". UCT Faculty of Health Sciences. Retrieved 2024-09-09.
  6. ^ "Team". Fcancer. Retrieved 2024-09-09.
  7. ^ "St. Bartholomew's and Royal London Hospitals (Hansard, 6 July 1993)". api.parliament.uk. 1993-07-06. Retrieved 2024-09-09.
  8. ^ Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM, Lowe DG, Reznek RH, Wrigley PF (September 1989). "A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer". Journal of Clinical Oncology. 7 (9): 1333–40. doi:10.1200/JCO.1989.7.9.1333. PMID 2549204.
  9. ^ Slevin ML, Piall EM, Aherne GW, Harvey VJ, Johnston A, Lister TA (September 1983). "Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid". Journal of Clinical Oncology. 1 (9): 546–51. doi:10.1200/JCO.1983.1.9.546. PMID 6583325.
  10. ^ Slevin ML, Stubbs L, Plant HJ, Wilson P, Gregory WM, Armes PJ, Downer SM (June 1990). "Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public". BMJ (Clinical Research Ed.). 300 (6737): 1458–60. doi:10.1136/bmj.300.6737.1458. PMC 1663147. PMID 2379006.
  11. ^ a b "Maurice Slevin". Google Scholar. Retrieved 2024-09-09.
  12. ^ "Massachusetts General Hospital and other places". ResearchGate. 2008-04-01. Retrieved 2024-09-09.
  13. ^ Slevin ML, Terry Y, Hallett N, Jefferies S, Launder S, Plant R, Wax H, McElwain T (September 1988). "BACUP--the first two years: evaluation of a national cancer information service". BMJ (Clinical Research Ed.). 297 (6649): 669–72. doi:10.1136/bmj.297.6649.669. PMC 1834344. PMID 3140928.
  14. ^ "The history of Macmillan". Macmillan Cancer Support. Retrieved 2024-09-09.
  15. ^ Lake, Howard (2008-01-12). "Macmillan Cancer Support and Cancerbackup to merge". UK Fundraising. Retrieved 2024-09-09.
  16. ^ Cornish, Jenny (2010-07-16). "Mergers: Who's the leader of the brand?". Third Sector. Retrieved 2024-09-09.
  17. ^ Read, Cathy (1994-02-15). "Health: When is it time to give in to cancer?: Some doctors believe". The Independent. Retrieved 2024-09-09.
  18. ^ Carvel, John (2003-02-04). "NHS on brink of implosion, claims leading specialist". The Guardian. Retrieved 2024-09-09.
  19. ^ "NHS is crushed by red tape, say consultants". The Telegraph. 2003-02-04. Retrieved 2024-09-09.
  20. ^ "Managers fight back over consultants claims". Public Finance. 2003-02-06. Retrieved 2024-09-09.
  21. ^ Templeton, Sarah-Kate (2007-08-26). "Experts push NHS to use US style cancer care". The Times & The Sunday Times. Retrieved 2024-09-09.
  22. ^ "Calls for 'NHS tax' to finance health care". The Telegraph. 2007-06-02. Retrieved 2024-09-09.
  23. ^ "Maurice Slevin". PubMed. Retrieved 2024-09-09.